These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091 [TBL] [Abstract][Full Text] [Related]
4. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. List AF; Baker AF; Green S; Bellamy W Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in myelodysplastic syndromes: where do we go from here? Sirulnik LA; Stone RM Curr Hematol Malig Rep; 2008 Jan; 3(1):5-9. PubMed ID: 20425440 [TBL] [Abstract][Full Text] [Related]
6. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study. Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461 [TBL] [Abstract][Full Text] [Related]
7. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Komrokji RS; List AF Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152 [TBL] [Abstract][Full Text] [Related]
8. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268 [TBL] [Abstract][Full Text] [Related]
10. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Talati C; Sallman D; List A Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252 [TBL] [Abstract][Full Text] [Related]
12. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Nimer SD J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711 [TBL] [Abstract][Full Text] [Related]
13. Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes. List AF Cancer Control; 2006 Dec; 13 Suppl():12-6. PubMed ID: 17242662 [TBL] [Abstract][Full Text] [Related]
14. The role of lenalidomide in the management of myelodysplasia with del 5q. Kelaidi C; Eclache V; Fenaux P Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896 [TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Oliva EN; Latagliata R; Laganà C; Breccia M; Galimberti S; Morabito F; Poloni A; Balleari E; Cortelezzi A; Palumbo G; Sanpaolo G; Volpe A; Specchia G; Finelli C; D'Errigo MG; Rodà F; Alati C; Alimena G; Nobile F; Aloe Spiriti MA Leuk Lymphoma; 2013 Nov; 54(11):2458-65. PubMed ID: 23432724 [TBL] [Abstract][Full Text] [Related]